Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04737889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Name: Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma — clinical trial record (NCT04737889)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHenan Cancer Hospital

Started2021-01-13

View on ClinicalTrials.gov ↗

Record status

This record was last updated April 23, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-04-18

Study Status, Oversight v2

Primary completion date2024-01-13→2025-06-30

2023-05-17

Study Status, Sponsor/Collaborators v1

Re-verified, no change to tracked fields

2021-01-30

Original filing

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.

Trial Details

NCT Number	NCT04737889
Lead Sponsor	Henan Cancer Hospital
Conditions	Primary Central Nervous System Lymphoma
Enrollment	30 participants
Start Date	2021-01-13
Primary Completion	2025-06-30 (estimated)
Study Completion	2026-01-13 (estimated)
Updated on ClinicalTrials.gov	2025-04-23